Jennifer Pickett
Family · Granbury, TXNPI 1265682009
Payments from drug & device makers
Across 132 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$473
- Lilly USA, LLC$333
- Pfizer$298
- Biogen$205
- Argenx US, Inc.$204
- SK Life Science, Inc.$130
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,84398%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $473 |
| Lilly USA, LLC | 15 | $333 |
| Pfizer | 19 | $298 |
| Biogen | 11 | $205 |
| Argenx US, Inc. | 8 | $204 |
| SK Life Science, Inc. | 5 | $130 |
| Eisai Inc. | 5 | $128 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Novartis | 5 | $107 |
| CSL Behring | 4 | $105 |
| Harmony Biosciences LLC | 3 | $92 |
| Averitas Pharma Inc. | 2 | $78 |
| Jazz Pharmaceuticals Inc. | 1 | $77 |
| Inspire Medical Systems, Inc. | 2 | $61 |
| AstraZeneca | 2 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Corium, LLC | 2 | $54 |
| Acorda Therapeutics, Inc | 2 | $46 |
| Intuitive Surgical | 1 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Cranial Technologies, Inc | 2 | $33 |
| Lundbeck LLC | 1 | $31 |
| Sanofi Pasteur Inc. | 1 | $29 |
| Pharming Healthcare, Inc. | 1 | $27 |
| Amgen | 1 | $26 |
| Grifols USA, LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Genentech USA, Inc. | 3 | $19 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$115
How this compares
$2,908 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 24 | $17,333 |
| Emgality PenGalcanezumab-Gnlm | 15 | $11,583 |
| Memantine Hcl | 103 | $4,110 |
| Levetiracetam | 68 | $2,842 |
| Gabapentin | 162 | $2,495 |
| Oxcarbazepine | 15 | $1,766 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $1,402 |
| Dimethyl Fumarate | 13 | $1,376 |
| Topiramate | 48 | $817 |
| Methocarbamol | 17 | $726 |
| Rasagiline Mesylate | 12 | $669 |
| Carbamazepine | 11 | $583 |
| Donepezil Hcl | 71 | $557 |
| Duloxetine Hcl | 48 | $482 |
| Ropinirole Hcl | 28 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric | $473 | $17,33324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Granbury
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.